home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Meetings and Conferences  
 

Solve Clinical Trial Enrollment Struggles With Better Utilization of Healthcare Data

 
  March 28, 2022  
     
 


xtalks.com, webinar
Tuesday, April 05, 2022 | 12pm EDT (9am PDT)


Who Should Attend?

The webinar will be of interest to members of the following industries:

  • Pharma, Biotech, Medical Device
  • CROs

Relevant areas:

  • Clinical operations
  • Medical affairs
  • Innovation

What You Will Learn

In this webinar, the featured speakers will discuss:

  • How EHR data can improve clinical trial enrollment
  • What difficulties sponsors might face when using EHR data to enroll studies
  • How to overcome these difficulties to keep a trial on time and on budget
  • The exciting future of healthcare data and clinical research
 
 
Organized by: xtalks.com
Invited Speakers:

Speakers

http://Michael%20Ibara,%20Elligo%20Health%20Research

Michael Ibara, Pharm.D., Chief Data Officer, Elligo Health Research®

Michael Ibara has more than 20 years of experience in clinical research and development. Throughout his career, Ibara has sought to improve healthcare by bringing together healthcare data and digital technologies. His interests include regulatory and policy implications for digital healthcare, exploring the factors needed to allow interoperability of healthcare data for all stakeholders involved, and implications for the use of big data, machine learning and natural language processing to improve our ability to perform regulated clinical research.

Before joining Elligo, Ibara was the head of digital healthcare for the Clinical Data Interchange Standards Consortium (CDISC). There, he led the FDA eSource project and Healthcare Link efforts with registries, clinical trials and mobile health to enable use of real-world data from healthcare for regulated research and decision making. Prior to CDISC, Ibara was head of business development coordination and innovation and also head of pharmacovigilance innovation at Pfizer, where he worked for 15 years in various positions, leading implementations of global systems and large-scale technologies.

Message Presenter
http://Dr.%20TJ%20Bowen,%20Deep%20Lens

Dr. TJ Bowen, Chief Scientific Officer & Co-Founder, Deep Lens

Dr. Bowen brings a diverse set of skills to the team.  Prior to joining Deep Lens, Dr. Bowen’s career has spanned from cancer research to software development and strategy and management consulting. His research focused on pathological identification of tumor differentiation in breast cancers derived from p53, BRCA1/2, ATM and other mutations.

 

Read more...

 

Message Presenter
http://Mitra%20Rocca,%20FDA

Mitra Rocca, Dipl.-Inform. Med., FAMIA, Senior Medical Informatician, FDA

Mitra Rocca joined Food and Drug Administration (FDA) in 2009 as the Senior Medical Informatician responsible for developing the health information architecture of the Sentinel System. She serves as the lead for the FDA CDER health information technology (health IT) board focusing on the use of health IT to enhance regulatory decision making. She serves as the FDA CDER lead to Health Level Seven (HL7), responsible for the review of HL7 draft standards.

Prior to joining FDA, Mitra served as the Associate Director, Healthcare Informatics at Novartis Pharmaceuticals Corporation focusing on the reuse of the Electronic Health Record (EHR) in clinical research. Mitra has served as the co-chair of the Health Level Seven (HL7) Clinical Interoperability Council (CIC) from 2012-2018. She holds her advanced degree in Medical Informatics from the University of Heidelberg in Germany.

Message Presenter
http://Riley%20Ennis,%20Freenome

Riley Ennis, Chief Product Officer, Freenome

With the knowledge and skills he gained as a biotechnology entrepreneur, Riley is helping to make Freenome’s vision of a cancer-free world a reality. As the company’s co-founder and Chief Product Officer, Riley heads the clinical and commercial development of Freenome’s non-invasive tests for early cancer detection and treatment selection.

A Thiel Fellow, Riley developed a cancer vaccine and founded his first biotech company, Immudicon, while still in high school. While earning his degree in molecular biology at Dartmouth, Riley co-authored several publications and worked as a visiting scientist with Novartis.

In addition to his work as a scientist, Riley worked as an analyst at Morgan Stanley and an associate at Bridgewater, where he observed the positive impact of a strong organizational culture firsthand. Riley’s previous biotech experience includes work at Foundation Medicine, Syros Pharmaceuticals, Adimab, and Emergent Biosolutions.

Message Presenter
http://Jeremy%20Brody,%20Cerner%20Enviza

Jeremy Brody, Head of Global Strategy, Cerner Enviza

Jeremy Brody is the head of global strategy and a member of the executive committee of Cerner Enviza. Jeremy’s primary responsibility is to lead corporate development activities, furthering the Enviza’s strategy and fueling the growth of the business. Areas of particular focus include real world evidence, advanced big data analytics, clinical research, patient-centric applications and digital health.

Before joining Cerner Enviza, Jeremy was the co-founder and CEO of Jstreetdata.com, the first online physician market research panel in the US. This venture-backed startup was acquired by Interpublic Group (NYSE:IPG) in August 2002 and, through subsequent acquisitions, became part of what today is called Cerner Enviza.

 

Read more...

 

 
Deadline for Abstracts: na
 
Registration: https://xtalks.com/webinars/solve-clinical-trial-enrollment-struggles-with-better-utilization-of-healthcare-data/
E-mail: shunte@xtalks.com
 
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.